Nectar Lifesciences Limited — Board Meeting, 07-07-2025: Outcome of Board Meeting

Nectar Lifesciences has announced a board meeting confirming its audited consolidated financial results for the quarter and half-year ended March 31, 2025. The company reported a consolidated revenue of ₹1,67,496.52 lacs, with a loss before tax of ₹16,153.40 lacs compared to a profit of ₹1,826.89 lacs last year. Deferred tax expenses stood at ₹4,785.32 lacs, resulting in a net loss of ₹11,368.08 lacs for the period. The board noted a markdown in non-current inventory value due to prolonged stock aging. The company generated a positive operating cash flow of ₹16,943.79 lacs but incurred net negative cash flow from financing activities. Management remains focused on liquidity and operational efficiencies.